---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041881"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-08T00:12:35.080137+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences receives Nasdaq delisting notice for non-compliance with $2.5M equity requirement

## Summary
- Notified on Nov 13, 2023 of non-compliance with Nasdaq Rule 5550(b)(1) due to stockholders' equity below $2.5M as of Sept 30, 2023.
- Company plans to timely request a hearing before Nasdaq Hearings Panel, staying delisting pending hearing conclusion.
- No assurance the Panel will grant continued listing or that compliance can be evidenced within any extension period.
- Company intends to actively explore options to regain compliance with Nasdaq listing requirements.

## SEC filing metadata
- accession: 0001493152-23-041881
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315223041881/0001493152-23-041881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315223041881/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041881
- JSON: https://secwatch.observer/filing/0001493152-23-041881.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041881.txt

## Key facts
- Listing & Compliance Notices
  Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 13, 2023, Ensysce Biosciences, Inc. (the “Company”) received notice from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of September 30, 2023, the Company was subject to delisting unless it timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the conclusion of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315223041881/0001493152-23-041881-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.